NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression

doi:10.4049/jimmunol.0901363

J Immunol. Author manuscript; available in PMC 2010 February 19.

Published in final edited form as:

J Immunol. 2009 July 15; 183(2): 787–791.

Published online 2009 July 1. doi: 10.4049/jimmunol.0901363

PMCID: PMC2824855

NIHMSID: NIHMS175726

NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression

Franz Bauernfeind,^†^* Gabor Horvath,^† Andrea Stutz,^† Emad S. Alnemri,^‡ Kelly MacDonald,^§ David Speert,^§ Teresa Fernandes-Alnemri,^‡ Jianghong Wu,^‡ Brian G. Monks,^† Katherine A. Fitzgerald,^† Veit Hornung,^*^¶ and Eicke Latz^†^¶

^†Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA

^*Department of Clinical Chemistry and Pharmacology, University of Bonn, 53127 Bonn, Germany

^‡Department of Biochemistry and Molecular Biology, Center for Apoptosis Research, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA

^§Division of Infectious and Immunological Diseases, Department of Pediatrics, University of British Columbia and BC's Children's Hospital, Vancouver, BC, Canada

Corresponding authors: Eicke Latz, MD PhD (communication with editorial office), University of Massachusetts Medical School, Department of Infectious Diseases and Immunology, 364 Plantation St, LRB 308, Worcester, MA 01605, USA, Phone: + 1 508 856 5889, Email: eicke.latz/at/umassmed.edu, Veit Hornung, MD, University of Bonn, Department of Clinical Chemistry and Pharmacology, Sigmund-Freud-Str. 25, 53127 Bonn, Germany, Phone: +49 228 287 12170, Email: veit.hornung/at/uni-bonn.de

^¶These authors contributed equally to this study

The publisher's final edited version of this article is available free at J Immunol

See other articles in PMC that cite the published article.

Abstract

The interleukin (IL)-1 family cytokines are regulated on transcriptional and posttranscriptional levels. Pattern recognition and cytokine receptors control pro-IL-1β transcription while inflammasomes regulate the proteolytic processing of pro-IL-1β. The NLRP3 inflammasome, however, assembles in response to extracellular ATP, poreforming toxins or crystals only in the presence of proinflammatory stimuli. How activation of gene transcription by signaling receptors enables the NLRP3 activation remains elusive and controversial. Here, we show that cell priming through multiple signaling receptors induce NLRP3 expression, which we identified to be a critical checkpoint for NLRP3 activation. Signals provided by NF-κB activators are necessary but not sufficient for NLRP3 activation and a second stimulus, such as ATP or crystal-induced damage is required for NLRP3 activation.

Introduction

Members of the Toll-like receptor (TLR) and C-type lectin receptor families signal in response to microbial or altered endogenous molecules when presented extracellularly or in endo-lysosomal compartments (1, 2, 3). In the cytoplasm, Nod-like receptors (NLRs) and Rig-I-like helicases respond to defined microbial components gaining access to the cytosol (3).

Most innate signaling receptors respond to a relatively restricted ligand spectrum (4). In contrast, diverse molecular entities including bacteria, viruses, purified microbial products, components of dying cells, small molecule immune activators and crystalline or aggregated materials can activate the NLR protein NLRP3 (5). The molecular mechanisms of how NLRP3 can recognize such a diverse array of activators and the role of transcriptionally active signaling receptors for the activation of the NLRP3 inflammasome are controversial and mechanistically poorly understood (2, 5–8). Upon activation, NLRP3 forms a so-called inflammasome complex with the adaptor molecule ASC, which controls the activation of caspase-1. Activated caspase-1, in turn, cleaves pro-IL-1β and pro-IL-18 into the biologically active, secreted forms (9).

Here, we demonstrate expression of NLRP3 itself is tightly controlled by the activity of multiple signaling receptors. We reveal that enhanced expression of NLRP3 in response to NF-κB is sufficient for NLRP3 inflammasome activation by ATP or pore-forming toxins or crystals. Thus, macrophages need to acquire a licensing signal provided by a transcriptionally active signaling receptor, which enables them to respond to NLRP3 activators.

Material and methods

Mice

Mice were kindly provided as indicated: NLRP3-KO and ASC-KO (Millenium Pharmaceuticals); TLR2-KO, TLR4-KO, TLR7-KO, IRAK4-KO, MAL-KO, TRIF-KO, MyD88-KO and TRAM-KO (S. Akira, Osaka University, Japan); TLR3-KO (R. Flavell, Yale University, New Haven); MD2-KO (K. Miyake, Tokyo University, Japan). C57BL/6 were purchased from Jackson Laboratories. All animal experiments were approved by the UMass Animal Care and Use Committee.

Reagents

Adenosin triphosphate (ATP), poly(dA-dT), muramyl dipeptide (MDP), nigericin, cycloheximide and Bay11-7082 were from Sigma-Aldrich. Pam₂CysK4, poly(I:C), ultra-pure LPS, R848, iE-DAP were from Invivogen. Anti-TLR4 Abs (UT18 and MTS510) were from eBioscience. The anti-NLRP3 pAB was raised against the NLRP3 pyrin domain that was expressed in E. coli. mAb against mouse pro-IL-1β was from the National Cancer Institute and the mouse α-actin mAb was from Sigma.

Cell stimulation and analysis

Human PBMCs were isolated by density-gradient centrifugation, stimulated in complete RPMI and the caspase-1 FMK-YVAD-FMK FLICA kit (Immunochemistry Technologies) was used to stain active caspase-1. CD14-positive cells were analyzed for FLICA positivity by flow cytometry. The respective local ethics committees approved experiments involving PBMCs. Immortalized macrophage cell lines were generated as described (10). Caspase-1 was detected in serum-free cell supernatants or cell lysates by SDS PAGE using caspase-1 pAb (sc-514; Santa Cruz). Human ASC and NLRP3 were cloned from cDNA into the lentiviral plasmid FugW and immortalized macrophages were transduced as described (12). Quantitative real-time PCR was performed as described (12). Primer sequences are available upon request. The mouse NLRP3 promoter (-3000 bp to 0 bp upstream of the transcription start site 1) was cloned from cDNA into pGL3-basic. HEK293T cells were transfected with luciferase reporter plasmid and expression plasmids (100ng each) using Lipofectamine.

Microscopy

A Leica SP2 AOBS confocal LSM was used. ASC pyroptosomes were quantified by epifluorescence microscopy and ImageJ software.

Results and discussion

Assembly of the NLRP3 inflammasome requires priming signals functioning upstream of ASC

Fluorescent ASC forms speck-like structures, termed pyroptosomes, upon activation (13). We generated immortalized mouse macrophages expressing ASC-YFP to test whether the NLRP3 inflammasome can assemble upstream of caspase-1 in the absence of priming. Resting cells or cells treated with ATP or LPS alone uniformly expressed ASC-YFP throughout the cells. However, when LPS-primed cells were treated with ATP, ASC-YFP formed large, irregularly shaped pyroptosomes indicating that LPS signaling was also required for ASC pyroptosome formation upon NLRP3 activation (Fig. 1A). Thus, mouse macrophages require two stimuli for NLRP3 inflammasome activation even at the level of ASC similar to what is observed at the level of caspase-1 (Supplementary Fig. 1A and (6)). Furthermore, pyroptosomes dose-responsively formed in response to LPS and ATP and caspase-1 cleavage closely correlated with the number of pyroptosomes (Fig. 1C, D and Supplementary Fig. 1B). Synthetic LPS or TLR2 and 7 activators also induced pyroptosomes together with ATP (Supplementary Fig. 1C, D) suggesting that TLR activators and not an undefined contaminant were responsible for pyroptosome formation in response to ATP. In line with previous observations, pyroptosome formation in response to the AIM2 inflammasome activator - transfected double-stranded DNA (poly(dA-dT)) - did not require LPS priming (Supplementary Fig. 1B and (12, 14)).

Figure 1

Caspase-1 activation and the formation of ASC pyroptosomes require priming

Different signaling receptor family members are able to license NLRP3 inflammasome activation

We next aimed at dissecting the influence of TLR4 signaling on NLRP3 inflammasome activation from TLR-independent mechanisms. We made use of an activating anti-TLR4/MD-2 antibody (clone UT18) and tested whether activation of TLR4 in the absence of LPS was sufficient for priming of the NLRP3 inflammasome. Pre-incubation with an activating antibody, but not with a blocking TLR4/MD-2 antibody (clone MTS510), led to the cleavage of caspase-1 in wild-type macrophages when stimulated with ATP. Furthermore, activation by the stimulating Ab was dependent on TLR4 and MD-2 consistent with the fact that it fails to bind and activate TLR4 or MD-2 alone (15) (Fig. 2A). Furthermore, activation of TLRs 2, 3 and 7 also induced priming of the NLRP3 inflammasome and macrophages lacking TLRs for the respective stimuli failed to activate caspase-1 after activation via ATP (Fig. 2B).

Figure 2

PRR activation is required for NLRP3 inflammasome activation

We next analyzed the requirement for TLR signaling for NLRP3 priming. Macrophages deficient in MyD88 or TRIF responded normally to LPS and ATP with cleavage of caspase-1, while macrophages doubly deficient in both MyD88 and TRIF or TLR4 failed to respond (Supplementary Fig. 2A). These results show that both TRIF-and MyD88-dependent signaling pathways can compensate for each other in their ability to induce priming for NLRP3 activation. Of note, the priming of macrophages was also a necessary step for NLRP3 inflammasome activation by other established NLRP3 activators such as the pore-forming toxin nigericin or crystalline activators (Supplementary Fig. 2B, C) suggesting that priming is generally required for NLRP3 inflammasome activation.

MDP, which engages NOD2, also mediated priming for ATP responsiveness and the activity was dependent on RIP2, the downstream signaling transducer of this signaling pathway (Fig. 2C). We further observed that priming with a cytokine stimulus (TNF-α) was sufficient to induce caspase-1 activation by ATP. Notably, TNF-α failed to prime cells obtained from mice doubly deficient in TNFR1 and 2, while LPS was able to prime these cells (Fig. 2D). Collectively, these results suggest that multiple transcriptionally active signaling receptors can prime macrophages for subsequent NLRP3 inflammasome activation.

Priming is required for NLRP3 activation in human monocytes

Interleukin-1 receptor-associated kinase 4 (IRAK4) is essentially required for signal transduction to NF-κB downstream of MyD88 (24). Indeed, ligands for TLRs that exclusively signal via the adapter MyD88 also failed to prime IRAK4-deficient macrophages for NLRP3-mediated ATP reactivity while signaling cascades that operate independently of MyD88 induced priming IRAK4-independently (Supplementary Fig. 3A). This differential requirement for priming allowed us to address the role of priming for NLRP3 inflammasome activation in the human system. We obtained monocytes from healthy volunteers and from a patient with a loss-of-function mutation (Q293X) in IRAK4(25) and tested their ability to activate caspase-1 upon ATP stimulation after priming with IRAK-4-dependent and -independent stimuli. Only primed monocytes displayed a robust caspase-1 activation upon ATP stimulation while the AIM2 inflammasome activation was independent this type of priming (Supplementary Fig. 3B). When primed with IRAK-4 independent ligands monocytes from the IRAK4-mutant patient responded robustly with caspase-1 activation after ATP stimulation. In contrast and consistent with IRAK4 deficiency in the murine system, we failed to observe priming activity towards ATP after TLR2 or TLR7/8 stimulation (Supplementary Fig. 3B). Thus, these data indicate that NLRP3 activation is also critically dependent on priming activity by signaling receptors in human cells.

NF-κB-dependent signals regulate NLRP3 expression

Treatment of macrophages with the protein synthesis inhibitor cycloheximide dose-responsively led to reduced caspase-1 activation obtained by the combination of LPS and ATP indicating that protein de novo synthesis was functionally limiting in mouse macrophages (Fig. 3A). In addition, priming of the NLRP3 inflammasome was dose-dependently reduced by a specific inhibitor of NF-κB (Bay11-7082) suggesting a key role for NF-κB for priming (Fig. 3B).

Figure 3

NLRP3 induction involves NF-κB activity

Overexpression of ASC is not sufficient to overcome the priming requirement for NLRP3 activation (Fig. 1) suggesting that the NF-κB-induced activity was acting upstream of ASC. Consistent with this idea, we found that LPS stimulation did not change Asc mRNA levels but led to strong, NF-κB-dependent, increases in Nlrp3 mRNA in mouse macrophages (Fig. 3C). These studies are in line with a report demonstrating NLRP3 induction by TNF and TLR ligands in human cells (16). To analyze the putative Nlrp3 promoter activity, we cloned the promoter region entailing −3000 to 0 bp upstream of the Nlrp3 transcription start site and constructed a luciferase reporter gene construct. We made use of the fact that heterologous overexpression of MyD88 activates downstream signaling and therefore expressed the Nlrp3 promoter-luciferase construct alone or together with MyD88. Indeed, co-expression of the Nlrp3 promoter-luciferase construct with MyD88 led to a ~10-fold induction of luciferase activity indicating that MyD88-mediated signaling can activate the promoter of Nlrp3. Notably, around 40% of patients with autoinflammatory diseases present with classical clinical symptoms without carrying any mutations in the coding region of NLRP3 (17). Recently, unique NLRP3 promoter sequence variants leading to enhanced NLRP3 promoter activity were identified in patients with autoinflammatory diseases that lack NLRP3 coding sequence mutations. This suggest that dysregulated NLRP3 expression could evoke autoinflammatory symptoms (18).

We further found that LPS stimulation led to both NLRP3 and pro-IL-1β protein induction in a dose- and time-dependent manner (Fig. 3E, F). In addition, LPS failed to induce NLRP3 or pro-IL-1β in cells lacking TLR4 or doubly-deficient in MyD88 and TRIF and NF-κB inhibition led to a dose-dependent reduction of NLRP3 protein induction by L P S (Supplementary Fig. 4A, B). Collectively, these data indicate that NLRP3 expression is tightly controlled by signals culminating in the activation of NF-κB.

NLRP3 expression is a limiting factor for NLRP3 inflammasome activation

To determine if enhanced expression of NLRP3 was not only required, but also sufficient for NLRP3 inflammasome activation by a ‘bona fide’ NLRP3 stimulus, we next generated macrophage cell lines expressing NLRP3 controlled by a constitutively active viral promoter (Fig. 4A–D). In contrast to cell lines overexpressing ASC alone, cells that overexpressed fluorescent NLRP3 together with fluorescent ASC responded to NLRP3 stimuli in the absence of a prior priming step with the formation of NLRP3/ASC pyroptosomes (Fig. 4A, C). We next assessed caspase-1 activity in wild-type and NLRP3-deficient macrophages with and without overexpressed NLRP3. Consistent with earlier results, LPS priming led to significant induction of NLRP3 protein in wild-type cells and LPS was required for caspase-1 cleavage in combination with an NLRP3 activator. NLRP3-mCitrine overexpressing wild-type cells, however, responded to nigericin (or ATP, data not shown) in the absence of prior priming (Fig. 4D; left). Moreover, heterologous expression of NLRP3-mCitrine functionally reconstituted NLRP3-KO macrophages, which also did not require priming to induce a functionally active NLRP3 inflammasome (Fig. 4D, right). Notably, overexpression of NLRP3 per se had no influence on caspase-1 cleavage in the absence of nigericin stimulation demonstrating the need for an NLRP3 activator at this level of expression. Altogether, these results establish that the requirement for priming of the NLRP3 inflammasome can be explained by the restricted expression of NLRP3 itself, and that the NLRP3 expression level is a limiting step for the NLRP3 inflammasome activation in macrophages (2, 5). We revealed that the NLRP3 inflammasome is, in fact, rather restricted in its ability to directly recognize microbial derived substances. We found that the activation of the NLRP3 inflammasome requires two steps, which are controlled by different mechanisms. First, NLRP3 expression itself needs to be transcriptionally induced, and a second, posttranscriptional step leads to the activation of NLRP3 allowing for NLRP3 inflammasome assembly. The key mediator of immunity, NF-κB, plays a critical role for the priming of the NLRP3 inflammasome. We thus speculate that other NF-κB activators such as UV light or reactive oxygen species can also induce NLRP3 priming.

Figure 4

Stable NLRP3 expression is sufficient for priming-independent NLRP3 activation

The fact that priming is a necessary step for NLRP3 inflammsome assembly suggests that macrophages need to acquire a signal that indicates either the presence of infection (via activation of PRRs by microbial products) or the activation of other cells (via the presence of pro-inflammatory cytokines) in order to commit to sense danger signals in their immediate environment via the activation of the NLRP3 inflammasome. This dual stimulation requirement may operate to prevent accidental or uncontrolled NLRP3 activation, which can have devastating consequences for the host as exemplified by the clinical presentation of patients with auto-inflammatory diseases (5, 17).

Supplementary Material

suppl

Click here to view.^{(739K, pdf)}

Acknowledgements

We would like to acknowledge P. Vandenabeele (University of Ghent, Ghent, Belgium) for supplying a caspase-1 p20 antibody.

This work was supported by grants from the NIH AI-065483 (to E.L.), AI-067497 (to K.A.F.) and and AG14357 and AR055398 (to E. S. A.), by a grant of the Dana Foundation (to E.L.), by the German Research Foundation (to V.H., Ho2783/2-1) and a grant by the Canadian Institutes for Health Research (to D. P. S.).

References

1. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annual review of immunology. 2003;21:335–376. [PubMed]

2. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006;442:39–44. [PubMed]

3. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20:17–22. [PubMed]

4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. [PubMed]

5. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annual review of immunology. 2009;27:229–265. [PubMed]

6. Kahlenberg JM, Lundberg KC, Kertesy SB, Qu Y, Dubyak GR. Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol. 2005;175:7611–7622. [PubMed]

7. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, Vandenabeele P, Nunez G. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity. 2007;26:433–443. [PubMed]

8. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–856. [PMC free article] [PubMed]

9. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annual review of immunology. 2009;27:519–550. [PubMed]

10. Roberson SM, Walker WS. Immortalization of cloned mouse splenic macrophages with a retrovirus containing the v-raf/mil and v-myc oncogenes. Cell Immunol. 1988;116:341–351. [PubMed]

11. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857–865. [PMC free article] [PubMed]

12. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009 [PMC free article] [PubMed]

13. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, Rosenberg S, Zhang J, Alnemri ES. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14:1590–1604. [PMC free article] [PubMed]

14. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458:509–513. [PMC free article] [PubMed]

15. Ohta S, Bahrun U, Shimazu R, Matsushita H, Fukudome K, Kimoto M. Induction of long-term lipopolysaccharide tolerance by an agonistic monoclonal antibody to the toll-like receptor 4/MD-2 complex. Clin Vaccine Immunol. 2006;13:1131–1136. [PMC free article] [PubMed]

16. O'Connor W, Jr, Harton JA, Zhu X, Linhoff MW, Ting JP. Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-kappa B suppressive properties. J Immunol. 2003;171:6329–6333. [PubMed]

17. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*) Annual review of immunology. 2009;27:621–668. [PMC free article] [PubMed]

18. Anderson JP, Mueller JL, Misaghi A, Anderson S, Sivagnanam M, Kolodner RD, Hoffman HM. Initial description of the human NLRP3 promoter. Genes Immun. 2008;9:721–726. [PubMed]